Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor GrowthMarc A. Becker, Paul Haluska, Thahir Farzan et al.|Molecular Cancer Therapeutics|2013Cited by 7
Combined erbB/VEGFR blockade has improved anticancer activity over single-pathway inhibition in ovarian cancer in vivoThahir Farzan, Paul Haluska, Sean C. Harrington et al.|Gynecologic Oncology|2011Cited by 0
Data from Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor GrowthMarc A. Becker, Paul Haluska, Thahir Farzan et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor GrowthMarc A. Becker, Paul Haluska, Xiaonan Hou et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor GrowthMarc A. Becker, Paul Haluska, Thahir Farzan et al.|Unknown|2023Cited by 0